AKBA
Akebia Therapeutics
$1.28
+$0.06 (+4.92%)Jul 27, 2026
Key metrics
The numbers that frame AKBA today
- Market cap
- $343.37M
- P/E (TTM)
- -16.7
- EV / FCF
- 3.8
- Gross margin
- 81%
- EV / Sales
- 1.0
- ROIC
- 5.7%
- Div yield
- 0%
- Debt / equity
- 1.8
- 52wk Low
- $0.82
- 52wk High
- $3.85
Growth
Revenue and earnings trend for AKBA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about AKBA
Is Akebia Therapeutics a good buy?
Hold. Akebia Therapeutics has excellent quality, but poor momentum makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Akebia Therapeutics is selling at a low price.
What is the market capitalization of AKBA?
Akebia Therapeutics's market capitalization is $343.37M.
What is the P/E ratio for AKBA stock?
Akebia Therapeutics's current P/E ratio is -16.7.
What is the 52-week high for AKBA stock?
The 52-week high for Akebia Therapeutics is $3.85. The current close of $1.28 is 66.8% below that high.
What is the 52-week low for AKBA stock?
The 52-week low for Akebia Therapeutics is $0.82. The current close of $1.28 is 55.5% above that low.
Does AKBA stock pay dividends?
Akebia Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for AKBA?
Akebia Therapeutics's Debt / Equity ratio is 1.79.